Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07275315 in Moderate-to-Severe COPD
NCT07363694Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2026
- Primary completion
- Oct 2030
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of tilrekimig in chronic obstructive pulmonary disease (COPD), sponsored by Pfizer. Started Feb 2026; status: recruiting.
02
Drugs
tilrekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07363694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363694.